Astellas to Appoint New CEO and President
Naoki Okamura, Astellas’ current chief strategy officer, will take over the role from Kenji Yasukawa.
Astellas announced an overhaul of its corporate management structure on Feb. 6, 2023. Among changes throughout the entire management chain, Naoki Okamura, Astellas’ current chief strategy officer and corporate executive vice-president, will take over as company CEO and president from Kenji Yasukawa. Yasukawa will stay on with the company as representative director and chairman of the board.
According to a company press release, after bottoming out in 2020, revenue has been on an upward trend; this change is an aggressive move to further accelerate company growth. It follows a transition in a business model that created products with a focus on specific disease areas to one that determines R&D areas from a “multifaceted perspective.”
In addition to changes at the top, the company has also appointed Claus Zieler as chief commercial officer, Adam Pearson as chief strategy officer, and Minoru Kikuoka as corporate executive vice-president.
Source: Astellas
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
